

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/002367

International filing date: 10 February 2005 (10.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP  
Number: 04290542.2  
Filing date: 27 February 2004 (27.02.2004)

Date of receipt at the International Bureau: 13 April 2005 (13.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

10.03.05

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

04290542.2

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk





PCT/EP2005/002367

10.03.05

Anmeldung Nr:  
Application no.: 04290542.2  
Demande no:

Anmeldetag:  
Date of filing: 27.02.04  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

INSTITUT NATIONAL DE LA SANTE ET DE LA  
RECHERCHE MEDICALE (INSERM)  
101, rue de Tolbiac  
75654 Paris Cédex 13  
FRANCE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

IL-15 binding site for IL 15-Ralpha and specific agonists/antagonists deriving  
therefrom

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI



**TITLE:**

5 **IL-15 binding site for IL15-Ralpha, and specific agonists/antagonists deriving therefrom**

**FIELD OF THE INVENTION:**

10 The present invention describes the identification of a human IL-15 binding site for IL-15Ralpha. It also provides IL-15 agonists and antagonists that target the IL-15Ralpha chain, *i.e.* the chain that confers to the IL-15R receptor complex its specificity for IL-15.

15 In the present application, reference is made to various scientific publications. These publications are listed at the end of the example part, before the claims. Reference thereto is made in the application text by way of a number between parentheses ; this number corresponds to the number in the publication list.

**TECHNICAL BACKGROUND:**

20 Interleukin-15 (IL-15) was identified as a new cytokine able to replace IL-2 in supporting the proliferation of a murine T cell line (1,2). Both cytokines belong to the four alpha helix bundle family (3). IL-15 was initially found to mimic most of the *in vitro* activities elicited by IL-2 *in vitro*, including induction of proliferation and cytotoxicity by activated T cells  
25 (1) and NK cells (2,4), co-stimulation of B cell proliferation and immunoglobulin synthesis (5) and chemo-attraction for T cells (6). This redundancy is explained by the common usage within their functional receptors of the IL-2R $\beta$ / $\gamma$  signaling complex.

This IL-2R $\beta$ / $\gamma$  complex is a common intermediate affinity receptor for IL-2 and IL-15 ( $K_d$  = 1 nM), and both cytokines compete to bind to this receptor (7). Cytokine specificity is  
30 conferred by additional private chains, IL-2R $\alpha$  and IL-15R $\alpha$ , that are structurally related (8). These two chains contain structural domains (called sushi domains) previously found in some complement and adhesion molecules (9). IL-2R $\alpha$  contains two such domains, whereas IL-15R $\alpha$  contains only one. One noticeable difference is that IL-2 binds to its

specific IL-2R $\alpha$  with an affinity ( $K_d = 10$  nM) far lower than IL-15 to IL-15R $\alpha$  ( $K_d = 0.05$  nM). Each specific chain can associate with the IL-2R $\beta/\gamma$  complex to form a cytokine-specific, functional high-affinity ( $\alpha\beta\gamma$ ) receptor (10-12).

Due to the sharing of this IL-2R $\beta/\gamma$  complex, both cytokines trigger similar downstream signaling pathways including activation of Jak-1/Jak-3 tyrosine kinases and subsequent nuclear translocation of the phosphorylated Stat-3 and Stat-5, activation of Lck and Syk tyrosine kinases, activation of the MAP kinase pathway, and induction of Bcl-2 (13,14). In contrast to IL-2R $\beta$  and IL-2R $\gamma$  that are required for signal transduction, the specific receptors IL-2R $\alpha$  and IL-15R $\alpha$  have short intracellular tails (13 and 41 amino-acids respectively) and IL-2R $\alpha$  is considered to play no role in signal transduction. While initial studies have pointed out the dispensable role of the intracellular tail of IL-15R $\alpha$  in signaling (8), more recent data suggest that IL-15R $\alpha$  might mediate certain intracellular functions (15-17).

In contrast to the general functional redundancy observed *in vitro*, several findings point to complementary and even opposing actions of IL-2 and IL-15 *in vivo*. Indeed, whereas IL-2 and IL-2R $\alpha$  gene expression is mainly restricted to the activated T cell compartment, IL-15 and IL-15R $\alpha$  transcripts are expressed by various cell types and tissues (monocytes, dendritic and stromal cells, keratinocytes, placenta, skeletal muscle, heart) suggesting additional roles for the IL-15 system beyond the immune system (7,8). Cells expressing IL-15R $\alpha$  in the absence of IL-2R $\beta$  and/or IL-2R $\gamma$  have been described and some of them respond to IL-15 (17,18), suggesting the existence of new functional IL-15 receptor complexes not involving IL-2R $\beta$  and/or IL-2R $\gamma$ .

Distinct roles for IL-2 and IL-15 are also suggested from experiments in knock-out mice. While IL-2 $^{-/-}$  and IL-2R $\alpha^{-/-}$  mice develop exacerbated T and B cell expansion associated with autoimmune manifestations, IL-15 $^{-/-}$  and IL-15R $\alpha^{-/-}$  mice on the contrary have normal T and B cell populations and display a profound defect in NK cells, NK-T cells, intraepithelial lymphocytes and CD8 $^{+}$  memory T cells (19,20). A recent study suggests that, contrary to the results obtained *in vitro*, the major role of IL-2 *in vivo* is to limit continuous expansion of activated T cells, whereas IL-15 is critical for initiating T cell division (21).

A number of studies have contributed to the identification of human disorders in which targeting the IL-15 system is of clinical relevance and potential benefit. Among them are autoimmune and inflammatory diseases, infectious diseases, transplant rejection, cancer and immunodeficiencies (22,23). In this context, the rational design of agonists or antagonists of the IL-15/receptor system is a major concern and requires a precise knowledge of the structure of the high-affinity IL-15 receptor complex.

A number of mutagenesis studies of human and murine IL-2 have led to the identification of several residues implicated in the binding to the IL-2R $\alpha$ ,  $\beta$  and  $\gamma$  chains. From these studies, residues K35, R38, F42 and K43, all located in the A-B loop of human IL-2, are involved in its binding to the IL-2R $\alpha$  chain, whereas residues D20 on helix A and N88 on helix C are involved in the binding to the IL-2R $\beta$  chain, and Q126 on helix D is crucial for binding to the IL-2R $\gamma$  chain (24-26). Similar regions were identified on mouse IL-2 (27).

15

On the contrary, very little data is available concerning the residues on IL-15 involved in the binding to the different IL-15 receptors.

Some mutations in human IL-15 (D8 and Q108) which are analogous to the ones described for human IL-2 suggested that the corresponding regions in IL-15 are involved in the binding to the IL-2R $\beta$  and  $\gamma$  subunits, respectively (28).

20

The present invention follows different complementary approaches including ligand receptor interaction analysis, induction of biological activity, peptide scanning, and site-directed mutagenesis, to define the epitope of IL-15 responsible for high-affinity binding to the IL-15R $\alpha$  chain.

25



### **SUMMARY OF THE INVENTION:**

5 The present invention provides with an epitope of human IL-15 responsible for high-affinity binding to the IL-15R $\alpha$  chain. This IL-15/IL15-Ralpha epitope essentially consists in two peptides : peptide 1 ( $_{44}$ LLELQVISL $_{52}$  ; SEQ ID NO:4 on Figure 1B) which is located in IL-15 helix B, and peptide 2 ( $_{64}$ ENLII $_{68}$  ; SEQ ID NO:6 on Figure 1B) which is located in helix C.

10 In the present application, all residue numbers are computed by reference to the full sequence of the mature human IL-15 protein (SEQ ID NO:2 shown on Figure 1A).

Peptide 1 and peptide 2 together configure in an epitopic surface that is responsible for high-affinity binding of IL-15 to IL-15R $\alpha$ . Peptide 2 is also involved in the recruitment of the IL-2R $\beta$  transducing subunit.

15 The present invention also provides IL-15 agonists and antagonists, and more particularly IL-15 agonists and antagonists which derive from said epitopic peptides by mutation (see Figures 2A, 2B, 2C, 2D).

20 Preferred agonists include those muteins wherein at least one of L45, S51 and L52 have been replaced by a charged group (D, E, R or K) ; see Figures 2A and 2C. A particularly preferred agonist comprises L45 replaced by D or E, and/or S51 replaced by D, and/or L52 replaced by D: these IL-15 muteins display binding and biological properties higher than those of wild-type IL-15, and thus behave as super-agonists. They are particularly valuable tools to expand lymphocyte subsets (*e.g.* NK cells, NK-T cells, CD8 $^{+}$  memory T  
25 cells) and are useful as therapeutic agents in patients with cancer or immunodeficiencies.

Preferred antagonists include those muteins wherein at least one of E64, I68 and N65 have been replaced by an oppositely charged group (K or R) or by charged group (D, E, R or K) or ; see Figures 2B and 2D. A particularly preferred antagonist comprises N65 mutated by  
30 a charged group (D, E, R or K), such as K. These muteins are antagonist or potential antagonists, and might therefore be useful in inflammatory conditions or diseases like rheumatoid arthritis and generalized Shwartzman reaction where IL-15 is thought to play an important role (22).

The present invention also relates to a process for the production of IL-15 muteins, to the nucleic acids coding for these muteins, to the transfection vectors and host cells containing such a nucleic acid, as well as to a method for screening for IL-15 agonist and antagonist.

- 5 Biological or medical applications of these epitopic peptides and muteins, such as drugs containing such muteins, also fall within the scope of the present invention.

### **DESCRIPTION OF THE FIGURES:**

10 - Figure 1A shows:

- the human IL-15 gene sequence (SEQ ID NO:1), and the CDS start and stop positions thereof,
- the sequence of the human mature IL-15 protein (SEQ ID NO:2) ; peptide 1 (from L44 to L52) and peptide 2 (from E64 to I68) are shown in bold characters,

15

- Figure 1B shows the DNA and aminoacid sequences of peptide 1 L44-L52 ; SEQ ID NO:3 and SEQ ID NO:4, respectively), and the DNA and aminoacid sequences of peptide 2 E64-I68 ; SEQ ID NO:5 and SEQ ID NO:6, respectively)

20

- Figure 2A shows the sequence of peptide 1 (L44-L52 ; SEQ ID NO:4), and some muteins deriving therefrom that have IL-15 agonist activity (SEQ ID NO:7-15),

25

- Figure 2B shows the sequence of peptide 2 (E64-I68 ; SEQ ID NO:6), and some muteins deriving therefrom (SEQ ID NO:16-22) that are IL-15 antagonist candidates,

30

- Figure 2C shows the sequence of some IL-15 muteins of the invention, which derives from human mature wild-type IL-15 by substitution of residue 45 (SEQ ID NO:23-25), or of residue 51 (SEQ ID NO:26-28), or of residue 52 (SEQ ID NO:29-31),

- Figure 2D shows the sequence of some IL-15 muteins of the invention, which derives from human mature wild-type IL-15 by substitution of residue 64 (SEQ ID

NO:32), or of residue 65 (SEQ ID NO:33-35), or of residue 68 (SEQ ID NO:36-38),

- 5        - Figures 3A and 3B illustrate the analysis of the binding of sIL-15R $\alpha$ -IL-2 to IL-15 12-mer peptides:

  - 10            o Figure 3A: twelve-mer peptides spanning the entire amino-acid sequence of human IL-15 were immobilized in multi-well plates, and tested for their reactivity with the different molecules as indicated. The left side of each sub-panel corresponds to the N-terminal 12-mer peptide of IL-15. The sIL-15R $\alpha$ -IL-2 fusion protein (20  $\mu$ g/ml, *i.e.* 330 nM) or rIL-2 (5  $\mu$ g/ml, *i.e.* 330 nM) were incubated and their binding revealed with the goat AF-202-NA anti-human IL-2 antibody plus a peroxidase-coupled rabbit anti-goat IgG. The reactivity of each well (ordinates, arbitrary scale) is measured as described in experimental procedures.
  - 15            o Figure 3B: the peptide regions of human IL-15 recognized by sIL-15R $\alpha$ -IL-2 are positioned on the primary structure of IL-15. The four alpha helices are shown,
- 20        - Figures 4A, 4B and 4C illustrate the determination of the affinities of FLAG-IL-15 and mutants for IL-15R $\alpha$  by competition binding studies : TF-1 cells were equilibrated with a fixed concentration (80 pM) of [ $^{125}$ I]-rIL-15 and increasing concentrations (as indicated on the abscissa) of the FLAG-IL-15 wild type (WT) or mutants.

  - 25            o Figure 4A: WT (■), L45D (◆), L45E (◇), E46K (▲)
  - o Figure 4B: WT (■) Q48K (□), V49D (◆), I50D (◇), S51D (▲), L52D (△)
  - o Figure 4C: WT (■), E64K (□), N65K (◆), L66D (◇), L66E (▲), I67D (△), I67E (●), I68D (○),
- 30        - Figures 5A, 5B, 5C illustrate the proliferative activities of FLAG-IL-15 and mutants on TF-1 $\beta$  cells: TF-1 $\beta$  cells were cultured in the presence of increasing concentrations (as indicated on the abscissa) of FLAG-IL-15 wild type (WT) or

mutants. Cell proliferation was evaluated by measuring the incorporation of [<sup>3</sup>H]-thymidine.

- Figure 5A: WT ( ■ ), L44D ( □ ), L45D ( ◆ ), L45E ( ◇ ), E46K ( ▲ ), L47D ( △ ),
- 5 ○ Figure 5B: WT ( ■ ) Q48K ( □ ), V49D ( ◆ ), I50D ( ◇ ), S51D ( ▲ ), L52D ( △ ),
- Figure 5C: WT ( ■ ), E64K ( □ ), N65K ( ◆ ), L66D ( ◇ ), L66E ( ▲ ), I67D ( △ ), I67E ( ● ), I68D ( ○ ).

## 10 **DETAILED DESCRIPTION OF THE INVENTION:**

The present invention describes the identification of an epitope in IL-15 that is responsible for high-affinity binding to the IL-15Ralpha chain. This epitope is essentially formed by two peptides: peptide 1 of SEQ ID NO:4, and peptide 2 of SEQ ID NO:6 (see Figure 1B).

- 15 In human mature wild-type IL-15, peptide 1 is located in helix B, and peptide 2 in helix C (see Figure 3B).

Site-directed mutagenesis of peptide 1 and peptide 2 show that both peptides are involved in IL-15Ralpha binding.

20

Surprisingly, mutations at positions L45, S51 and L52 (peptide 1) did not result in reduction but in an increase in binding and bio-activity, such that the resulting mutants behave as super-agonists. They are valuable tools to expand lymphocyte subsets (*e.g.* NK cells, NK-T cells, CD8+ memory T cells), and may be useful as therapeutic agents in

25 patients with cancer or immunodeficiencies.

- Site-directed mutagenesis of peptide 2 shows that peptide 2 participates both in IL-15Ralpha and IL-2Rbeta binding, and that all aminoacids of peptide 2 (E64 to I68) are involved in this process. L66 and I67 are apparently more particularly involved in IL-15
- 30 binding to IL-15Ralpha, whereas E64, N65 and I68 are apparently more particularly involved in the recruitment of IL-15Rbeta. Mutations at positions E64, N65 and I68 induce properties that designate the resulting mutants as potential IL-15 antagonists. They

may be useful in inflammatory diseases like rheumatoid arthritis and generalised Shwartzman reaction.

5 Compounds interfering with the binding of these IL-15 epitopic peptides to IL-15Ralpha may act as IL-15 agonist or antagonist. As this IL-15Ralpha chain is the subunit that confers the specificity of the IL-15R receptor complex for IL-15 compared to IL-2, such agonists and antagonists are particularly advantageous in terms of specificity.

The present application is directed to such agonistic and antagonistic compounds, and notably describes muteins having such agonistic or antagonistic effects.

10

The terms agonist and antagonist are herein given their ordinary meaning in the field.

15 A compound is termed IL-15 agonist when it induces a biological response that is of a similar level compared to the one induced by native IL-15. Preferred agonists are those which induce an even higher level of biological response (super-agonist).

An IL-15 agonist typically has a affinity for binding to IL-15Ralpha that is at least not significantly different from the one of native IL-15, and that is preferably significantly higher than the one of native IL-15.

20 An antagonist interferes with the binding of IL-15 to its target receptor or receptor chain, such that it antagonizes IL-15's biological activity. More particularly, a compound is termed IL-15 antagonist when it can compete with native IL-15 for binding to its IL-15Ralpha and/or IL15-Rbeta and/or IL-15-Rgamma receptor chain target, and to thereupon either block or significantly inhibit the biological response induced by said native IL-15. Partial agonists are hence herein encompassed within the term "antagonist".

25 Antagonist candidates are those compounds that have an affinity for binding to IL-15Ralpha and/or IL-15Rbeta and/or IL-15-Rgamma that is either not significantly different from, or higher than the one of native IL-15, and that induce no, or a significantly lower level of biological response than native IL-15.

30

Said biological response is a biological response induced by IL-15. The skilled person can choose any IL-15 inducible biological response that he/she finds appropriate or convenient to assess or monitor.

Typical IL-15 inducible biological response are proliferation of IL-15 sensitive cells, such as *e.g.* CTL-L2 mouse cytotoxic T lymphoma cell line (ATCC accession number TIB-214), or TF1-beta cells.

TF-1 cells are available from the American Type Culture Collection ATCC ; P.O. Box 5 1549 ; Manassas, VA 20108 ; U.S.A. ; *cf.* <http://www.lgcpromochem.com/atcc/> under ATCC accession number CRL-2003.

Beta chain templates are available from RNA of HuT102 (ATCC TIB-162) or Jurkat clone E6.1 (ATCC TIB 152) by RT-PCR using the proofreading polymerase Pfu (Stratagène n° 600390) and 5'GAGAGACTGGATGGACCC 3' as sense primer (SEQ ID NO:51), and 5' 10 AAGAAACTAACTCTTAAAGAGGC3' as anti-sense primer (SEQ ID NO:52) according to human IL-2R beta sequence (NCBI accession number K03122). The PCR product is efficiently cloned using the Zero Blunt PCR Cloning Kit (In Vitrogen cat n° K2700-20) or the TOPO XL PCR cloning kit (In Vitrogen cat n° K4750-10). The cDNA for IL-2R beta gene is then subcloned into the multiple cloning site of the pLXRN retrovirus expression 15 vector of the Pantropic Retroviral Expression System (BD Biosciences Clontech n° 631512) and transfected into GP2-293 cells, as described in the kit to generate recombinant retroviruses. IL-2R beta recombinant retroviruses can then be used to infect TF-1 cells to generate TF-1 $\beta$  after selection in medium containing G418.

20 The skilled person may alternatively choose to assess or monitor an IL-15 biological response that is more downstream in the signalling pathway, such as activation of a tyrosine kinase (*e.g.* Jak-1/Jak-3 ; Lck ; Syk), activation of a MAP kinase, or a nuclear translocation event (*e.g.* translocation of phosphorylated Stat-3 and/or Stat-5). The biological response may then be an acellular response.

25 The present application thus relates to two peptides that are both part of the epitope in human IL-15 that is responsible for high-affinity binding of IL-15 to the IL-15Ralpha chain. They respectively have the sequence of the region of human mature wild-type IL-15 from L44 to L52 (SEQ ID NO:4), or the sequence of the region of human mature wild- 30 type IL-15 from E64 to I68 (SEQ ID NO:6) ; see Figure 1B.

Nucleic acids (DNA or RNA) coding for such an epitopic peptide are also encompasses within the scope of the present invention. Exemplary nucleic acids includes those of SEQ ID NO:3 and SEQ ID NO:5 (see Figure 1B).

Methods to produce antibodies that bind to a given peptide or protein are well known to those skilled in the art, see *e.g.* "*Antibodies: a laboratory manual*" / edited by Ed Harlow, David Lane, publisher Cold Spring Harbor Laboratory, 1988. Also routinely achieved is  
5 the production of monoclonal antibodies, see *e.g.* the hybridoma technique described in Köhler and Milstein 1975, Nature 256:495-497.

These methods can be used for the production of antibodies, more particularly monoclonal antibodies, which bind to an epitopic peptide and/or a mutein of the invention.

A variety of immunoassay formats may be used to select antibodies specifically  
10 immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein, see *e.g.* "*Antibodies: a laboratory manual*" (edited by Ed Harlow, David Lane, publisher Cold Spring Harbor Laboratory, 1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. Antibodies or  
15 monoclonal antibodies with a defined specificity can thus be produced.

Advantageous anti-IL15 antibodies or monoclonal antibodies are those which have agonistic or antagonistic IL-15 properties.

The present invention also relates to IL-15 muteins and IL-15 mutein fragments, which are  
20 derivable from the epitopic peptides of the invention.

The present application thus relates to IL-15 muteins, which comprise a sequence that is derivable from human mature wild-type IL-15 by at least one substitution, deletion or addition within the region spanning from residue 44 to residue 52, and/or from residue 64  
25 to residue 68 (all end point residues of said regions being explicitly included), this residue numbering corresponding to (and being maintained as that of) the human mature wild-type IL-15.

Preferably, the mutation(s) is(are) affinity-conservative or affinity-enhancing, such that the IL-15 mutein resulting therefrom has an affinity for binding to IL-15Ralpha that is  
30 either not significantly different from, or higher than the affinity of human mature wild-type IL-15 for binding to IL-15Ralpha.

When starting from human mature wild-type IL-15, residue E46 and I50 should preferably not be mutated as they tend to induce a reduction in affinity for IL-15Ralpha.

Equivalent muteins can be derived from other mature wild-type IL-15, such as notably non-human but animal mature wild-type IL-15, and more particularly non-human but mammal mature wild-type IL-15, *e.g.* simian, mouse, rat, bovine, sheep, pig or dog IL-15.

5 Said substitution can *e.g.* be a replacement of at least one hydrophobic side chain selected from L, V and I, and/or of at least one non-charged polar side chain selected from S, Q and N by a charged group selected from D, E, R and K, and/or a replacement of at least one charged polar side chain selected from E by an oppositely charged group selected from K and R.

10

The present invention further provides with IL-15 muteins that are IL-15 agonists or super-agonists.

Preferred agonistic muteins comprise a sequence that is derivable from human mature wild-type IL-15 by substitution of at least one of residues 45, 51, 52.

15 In human mature wild-type IL-15, residue 45 is L, residue 51 is S and residue 52 is L (see SEQ ID NO:2 on Figure 1A).

The present invention particularly provides with IL-15 muteins that comprise a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 45 by D, E K or R, preferably by D or E. They notably include the IL-15 muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by substitution of the region spanning from residue 44 to residue 52 by the sequence of SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or SEQ ID NO:10, *e.g.* the IL-15 muteins of sequence SEQ ID NO:29 or SEQ ID NO:30 or SEQ ID NO:31 or SEQ ID NO:32, respectively (see Figure 2C). Most preferred agonistic muteins include those muteins which comprise the sequence of SEQ ID NO:29 or SEQ ID NO:30 (see Figure 2C).

Other preferred IL-15 agonistic muteins include those muteins that comprise a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 51 by D, E K or R, preferably by D. They notably include the IL-15 muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by substitution of the region spanning from residue 44 to residue 52 by the sequence of SEQ ID NO:11 or SEQ ID NO:12 or SEQ ID NO:13 or SEQ ID NO:14, *e.g.* the IL-15 muteins of sequence SEQ

30



ID NO:33 or SEQ ID NO:34 or SEQ ID NO:35 or SEQ ID NO:36, respectively (see Figure 2C). Most preferred agonistic muteins include those which comprise the sequence of SEQ ID NO:33 (see Figure 2C).

5 Still other preferred IL-15 agonistic muteins include those muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 52 by D, E, K or R, preferably by D. They notably include the IL-15 muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by substitution of the region spanning from residue 44 to residue 52 by the sequence of SEQ ID NO:15 or  
 10 SEQ ID NO:16 or SEQ ID NO:17 or SEQ ID NO:18, e.g. the IL-15 muteins of sequence SEQ ID NO:37 or SEQ ID NO:38 or SEQ ID NO:39 or SEQ ID NO:40, respectively (see Figure 2C). Most preferred agonistic muteins include those which comprise the sequence of SEQ ID NO:37 (see Figure 2C).

15 The present invention further provides with IL-15 muteins that are IL-15 antagonists or antagonist candidates.

Preferred antagonistic muteins comprise a sequence that is derivable from human mature wild-type IL-15 by substitution of at least one of residues 64, 65, 68.

In human mature wild-type IL-15, residue 64 is E, residue 65 is N and residue 68 is I (see  
 20 SEQ ID NO:2 on Figure 1A).

Site-directed mutagenesis of peptide 1 shows that L45, E46, V49, S51 and L52 are involved in IL-15Ralpha binding, and that E46 was crucial, since replacement of its acidic side chain by a basic one (E46K) results in a complete loss of IL-15 binding to IL-  
 25 15Ralpha and bio-activity. Mutation at position I50 (I50D) strongly reduced the ability of IL-15 to bind to IL-15Ralpha as well as to induce cell proliferation. Replacement of the hydrophobic side chain of V49 by a negatively charged side chain (V49D) also results in a strong (13 fold) reduction of the affinity of IL-15 for IL-15Ralpha.

Mutations at residue 46 or 49 or 50, such as E46K or V49D or I50D, thus tend to induce a  
 30 significant loss in binding affinity. They are therefore generally not satisfactory, at least when introduced as a single-point mutation.

Preferred IL-15 antagonistic muteins include those muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 64 by K or

R. They notably include the IL-15 muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by substitution of the region spanning from residue 64 to residue 68 by the sequence of SEQ ID NO:19 or SEQ ID NO:20, *e.g.* the IL-15 mutein of sequence SEQ ID NO:41 or SEQ ID NO:42 (see Figure 2D). Most preferred antagonistic muteins include those which comprise the sequence of SEQ ID NO:41 (see Figure 2D).

Other preferred IL-15 antagonistic muteins include those muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 65 by D, E, K or R, preferably by K. They notably include the IL-15 muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by substitution of the region spanning from residue 64 to residue 68 by the sequence of SEQ ID NO:21 or SEQ ID NO:22 or SEQ ID NO:23 or SEQ ID NO:24, *e.g.* the IL-15 mutein of sequence SEQ ID NO:43 or SEQ ID NO:44 or SEQ ID NO:45 or SEQ ID NO:46, respectively (see Figure 2D). Most preferred IL-15 antagonistic muteins include those which comprise the sequence of SEQ ID NO:43 (see Figure 2D).

Still other preferred IL-15 antagonistic muteins include those muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 68 by D, E, K or R, preferably by K. They notably include the IL-15 muteins which comprise a sequence that is derivable from human mature wild-type IL-15 by substitution of the region spanning from residue 64 to residue 68 by the sequence of SEQ ID NO:25 or SEQ ID NO:26 or SEQ ID NO:27 or SEQ ID NO:28, *e.g.* the IL-15 mutein of sequence SEQ ID NO:47 or SEQ ID NO:48 or SEQ ID NO:49 or SEQ ID NO:50, respectively (see Figure 2D). Most preferred IL-15 antagonistic muteins include those which comprise the sequence of SEQ ID NO:47 (see Figure 2D).

The present application also relates to the nucleic acids (DNA or RNA) coding for the IL-15 muteins of the invention, optionally contained within a vector, such as transfection vector, an expression vector.

The DNA encoding an IL-15 mutein may then be operably linked to a suitable transcriptional or translational regulatory sequence such as transcriptional promoters or enhancers, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and appropriate sequences that control

transcription and translation initiation and termination. Examples of such vectors include pEF1/myc-His (In Vitrogen, V921-20), pcDNA3.1 (In Vitrogen, V800-20).

It may also be linked to a leader sequence that enables improved extracellular secretion of the translated polypeptide. Examples of such leader sequences include Kozak and leader sequences from rat pre-prolactin (NCBI accession number AF022935, nucleotides 178 to 270 ; cf. [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) ; National Center for Biotechnology Information, U.S. National library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, U.S.A.).

The recombinant expression vectors carrying the recombinant IL-15 mutein structural coding sequence may then be transfected or transformed into a host cell.

Suitable host cells for expression of an IL-15 mutein include prokaryotes, yeast or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include for example *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, and various other species within the genera *Pseudomonas*, *Streptomyces* and *Staphylococcus*. Examples of suitable host cells also include yeast such as *Saccharomyces cerevisiae*, a mammalian cell line such as Chinese Hamster Ovary (CHO) cells, e.g. Chinese ovary hamster cell line CHO/dhfr<sup>-</sup> (CHO duk<sup>-</sup>) (ATCC n° CRL-9096), or such as epithelial cell lines, e.g. simian epithelial cell line COS-7 (ATCC n° CRL 1651), or human cell lines, e.g. 293 c18 human kidney cell line (ATCC n° CRL-10852) or FreeStyle 293-F human kidney cell line (In Vitrogen n° R790-07).

Appropriate cloning and expression vectors for use with bacterial, insect, yeast and mammalian cellular host are described for example, in Pouwels *et al. Cloning Vectors: A laboratory Manual*, Elsevier, N.Y. 1985.

The present application also relates to the conservative fragment of the IL-15 mutein of the invention. Such conservative IL-15 mutein fragments still comprise the mutated 44-52 region and/or mutated 64-68 region, and has retained an affinity for binding to IL-15Ralpha that is either not significantly different from, or higher than the affinity of human mature wild-type IL-15 for binding to IL-15Ralpha.

The present application more particularly relates to IL-15 mutein fragments which are IL-15 agonists, such as a fragment comprising the sequence of any one of SEQ ID NO:7-18, for example the peptide of SEQ ID NO:7 (L45D), or SEQ ID NO:8 (L45E), or SEQ ID NO:11 (S51D), or SEQ ID NO:15 (L52D) ; see Figure 2A.

The present application more particularly relates to IL-15 mutein fragments which are IL-15 antagonists or antagonist candidates, such as a fragment comprising the sequence of any one of SEQ ID NO:19-28, for example the peptides of SEQ ID NO:19 (E64K), SEQ ID NO:23 (N65K) or SEQ ID NO:25 (I68D), preferably the peptide of SEQ ID NO:23 (N65K) ; see Figure 2B.

Similarly to what has been above described for the muteins of the invention, the present application also encompasses within its scope the nucleic acid (DNA or RNA) coding for the IL-15 mutein fragments of the invention, optionally contained within a vector; as well as any such vector, and any host cell containing such a nucleic acid.

The epitopic peptides and muteins of the invention can be produced by any means that the skilled person may find appropriate, such as *e.g.* chemical peptide synthesis, or peptide biosynthesis.

15

Chemical peptide synthesis is now a routine (see *e.g.* Andersson *et al.*, 2000, Biopolymers (Peptide Science) 55 : 227-250), and many companies are specialized in such synthesis. Preferably, the epitopic peptide and mutein fragments of the present invention are synthesized by solid phase peptide synthesis (SPPS) techniques using standard Fmoc protocols (See, *e.g.*, Carpino *et al.*, 1970, J. Am. Chem. Soc. 92(19):5748-5749; Carpino *et al.*, 1972, J. Org. Chem. 37(22):3404-3409).

Alternatively, the skilled person may choose to produce the muteins or mutein fragment biologically by *in vitro* or *in vivo* translation of a mutated expression cassette obtained from wild-type IL-15 by site-directed mutagenesis (Sodoyer, 2004, Biodrugs, 18 (1): 51-62).

An illustration thereof is described in the example below.

Amino-acid switching may then be performed by any mutagenesis means available to the skilled person, *e.g.* by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California, U.S.A.). The mutated expression cassette can then be transfected host cells such as 293 c18 cells (ATCC n°10852) (Invitrogen, Leek, The Netherlands). Transfected cells may then be cultured so as to express the mutated cassette (293 c18 cells can *e.g.* be cultured in a DMEM containing 10%FCS, 2mM glutamine, 1mg/mL glucose, and 250 microgrammes/mL geneticin). The mutated expression product can then be

recovered and optionally purified (*e.g.* collection of culture supernatants and purification thereof).

5 A process for the production of an IL-15 mutein or of an IL-15 mutein fragment according to the invention *e.g.* comprises:

- providing a nucleic acid according to the invention, which codes for said mutein or mutein fragment, said nucleic acid being optionally within a expression vector,
- operably introducing said nucleic acid into a host cell so that it produces the expression product thereof,
- 10 - recovering said expression product.

The IL-15 mutein may be concentrated using a commercially available protein concentration filter, such as an Amicon or Millipore Pellicon ultrafiltration unit.

15 The resulting expressed optionally concentrated mutein may then be purified from culture media or extracts. The culture media or cell extract may be applied to a purification matrix such as a hydrophobic chromatography medium, or an anion exchange resin.

Concentration may then be further increased by RP-HPLC.

20 The concentrated mutein can also be purified through its N-terminal FLAG tag on an immuno-affinity column grafted with the anti-FLAG antibody M2 (Sigma product no A 2220).

Other tags (*e.g.* polyHistine tag) can be added by genetic engineering to the N or C terminal ends of the muteins in order to help its purification process.

25 The present application also relates to the biological and medical applications of the epitopic peptides, the IL-15 muteins, and the IL-15 mutein fragments of the invention, either in their aminoacid expression, or in their nucleic acid coding version.

30 The agonistic muteins of the invention are useful to expand lymphocyte subsets, such as particular T/NK subsets. The present invention thus relates to their use as an agent for expanding one or several lymphocyte populations, such as NK cells, NK-T cells, CD8+ memory cells, and to a composition or kit intended for such a use which comprises such an agonistic mutein.

The present invention particularly relates to a drug or vaccine, comprising an IL-15 mutein or IL-15 mutein fragment of the invention, and optionally a pharmaceutically acceptable vehicle and/or carrier and/or diluent and/or adjuvant.

5 Such a drug or vaccine is intended for prevention and/or treatment and/or alleviation of a condition or disease in which a reduction or increase of IL-15 activity is desired.

A number of studies have contributed to the identification of disorders in which targeting the IL-15 system is of clinical relevance and potential benefit. Among them are autoimmune and inflammatory diseases, infectious diseases, transplant rejection, cancer and immunodeficiencies (see bibliographic references 22, 23).

10

The present application particularly relates to a drug or vaccine comprising an IL-15 mutein or IL-15 mutein fragment of the invention, which is an IL-15 agonist of the invention, and optionally a pharmaceutically acceptable vehicle and/or carrier and/or diluent and/or adjuvant.

15 Such a drug or vaccine is intended for prevention and/or treatment and/or alleviation of a condition or disease in which an increase of IL-15 activity is desired, such as notably cancer or immunodeficiency. Such a drug or vaccine may act by stimulating the proliferation and/or survival of lymphocytes (such as T cells, CD8<sup>+</sup> T cells, NK cells, dendritic cells) and/or their activity against tumoral cells.

20

The present application particularly relates to such a drug comprising an IL-15 mutein or IL-15 mutein fragment of the invention, which is an IL-15 antagonist of the invention, and optionally a pharmaceutically acceptable vehicle and/or carrier and/or diluent and/or adjuvant.

25 Such a drug is intended for prevention and/or treatment and/or alleviation of a condition or disease in which a reduction of IL-15 activity is desired, such as inflammatory diseases like rheumatoid arthritis and generalized Shwartzman reaction.

The present application further relates to a process for screening for an IL-15 agonist or  
30 antagonist, which comprises:

i. providing a plurality of IL-15 muteins, and/or of IL-15 mutein fragments according to the invention,

ii. comparing their respective binding affinity for IL15-Ralpha to the binding affinity of mature wild-type IL-15,

iii. selecting those muteins or mutein fragments which have a binding affinity that is not significantly different from, or that is higher than the one of mature wild-type IL-15.

To screen for an IL-15 agonist, the process may further comprises:

- 5           iv. selecting at least one detectable IL15-inducible activity,  
            v. comparing the level of said activity that is induced in response to the muteins or fragments selected in step iii., to the one induced by mature wild-type IL-15,  
            vi. selecting those muteins or fragments which induce an activity level that is not significantly different from, or that is higher than the one of mature wild-type IL-15.

10

To screen for an IL-15 antagonist, characterized in that it further comprises:

- iv. selecting at least one detectable IL15-inducible activity,  
            v. comparing the level of said activity that is induced in response to the muteins or fragments selected in step iii., to the one induced by mature wild-type IL-15,  
15           vi. selecting those muteins or fragments which induce an activity level that is lower than the one of mature wild-type IL-15, or which induce no detectable level of activity.

20           The present invention is illustrated by the examples below. They only have illustrative purposes, and do not limit the scope of the present invention.

## **EXAMPLES:**

### **Experimental Procedures**

25

#### ***Cytokines and antibodies***

Recombinant murine IL-3 and human GM-CSF were purchased from R&D Systems (Abington, UK), recombinant human IL-15 (rIL-15) was purchased from Peprtech Inc  
30           (Rocky Hill, NJ), and recombinant human IL-2 (rIL-2) from Chiron (Emeryville, CA). Polyclonal goat anti-human IL-2 AF-202-NA was purchased from R&D Systems and the mouse anti-human IL-2 mAb IL2.66 was from Immunotech (Marseille, France).

Monoclonal mouse anti-human IL-15R $\alpha$  M161 was kindly provided by GenMab A/S (Copenhagen, Denmark) and mouse anti-FLAG mAb M2 conjugated to peroxidase was purchased from Sigma (Saint Quentin Fallavier, France).

5

### *Cell culture*

The non-adherent TF-1 human cell line is available from the American Type Culture Collection ; P.O. Box 1549 ; Manassas, VA 20108 ; U.S.A., and has ATCC accession number CRL-2003 (*cf.* <http://www.lgcpromochem.com/atcc/>).

- 10 TF-1 $\beta$  human cells are available by operably transfecting TF-1 cells with beta chains so that the TF-1beta cells resulting therefrom proliferates in response to IL-15 (see bibliographic reference 29).

- Beta chain templates are available from RNA of HuT102 (ATCC TIB-162) or Jurkat clone E6.1 (ATCC TIB 152) by RT-PCR using the proofreading polymerase Pfu (Stratagène n° 600390) and 5'GAGAGACTGGATGGACCC 3' as sense primer (SEQ ID NO:51), and 5' AAGAAACTAACTCTTAAAGAGGC3' as anti-sense primer (SEQ ID NO:52) according to human IL-2R beta sequence (NCBI accession number K03122). The PCR product is efficiently cloned using the Zero Blunt PCR Cloning Kit (In Vitrogen cat n° K2700-20) or the TOPO XL PCR cloning kit (In Vitrogen cat n° K4750-10). The cDNA for IL-2R beta gene is then subcloned into the multiple cloning site of the pLXRN retrovirus expression vector of the Pantropic Retroviral Expression System (BD Biosciences Clontech n° 631512) and transfected into GP2-293 cells, as described in the kit to generate recombinant retroviruses. IL-2R beta recombinant retroviruses can then be used to infect TF-1 cells to generate TF-1 $\beta$  after selection in medium containing G418.

25

The adherent CHO duk- cell line is available from the ATCC (CHO/dhfr-; accession number CRL-9096).

- 30 All cells were grown in 5% CO<sub>2</sub> at 37°C in a water-saturated atmosphere. The non-adherent TF-1 human cell line, TF-1 $\beta$  human cells and adherent CHO duk- cell line were cultured in a RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS), 2 mM glutamine, and specific reactants as follow: 1 ng/ml of GM-CSF (TF1), 1 ng/ml GM-CSF and 250  $\mu$ g/ml geneticin (TF-1 $\beta$ ), 10  $\mu$ g/ml of adenosine, deoxyadenosine, and



thymidine (Dhfr<sup>-</sup> CHO duk<sup>-</sup>). The non-adherent CTLL-2 murine cell line was cultured in a RPMI 1640 medium containing 8% FCS, 2 mM glutamine, 15 ng/ml rIL-2, and 50  $\mu$ M 2-mercaptoethanol. Adherent 293 c18 human cells (Invitrogen, Leek, The Netherlands) were cultured in a DMEM containing 10% FCS, 2 mM glutamine, 1 mg/ml glucose, and 250  $\mu$ g/ml geneticin.

### *Preparation of soluble IL-15R $\alpha$ -IL-2 fusion protein*

Human IL-15R $\alpha$  templates are available by RT-PCR from RNA of TF-1 cells (ATCC accession number CRL-2003) or of normal human monocytes purified from blood, using the proofreading polymerase Pfu (Stratagène n° 600390) and 5' AGTCCAGCGGTGTCCTGTGG 3' as sense primer – SEQ ID NO:53 –, and 5' TCATAGGTGGTGAGAGCAGT 3' as anti-sense primer – SEQ ID NO:54 – according to human IL-15R $\alpha$  sequence (NCBI accession number U31628). The PCR product is cloned using the Zero Blunt PCR Cloning Kit (In Vitrogen cat n° K2700-20), to create a pNo15R plasmid.

Human IL-2 templates are available by RT-PCR from RNA of Jurkat cells clone E6-1 (ATCC accession number TIB-152) stimulated with OKT3 antibody and PMA (30), using the proofreading polymerase Pfu (Stratagène n° 600390) and 5' AACTGCAGGCACCTACTTCAAGTTCTAC 3' as sense primer (*Pst* I underlined) – SEQ ID NO:55 –, and 5' TCCCCCGGGTCAAGTCAGTGTTGAGATG 3' as anti-sense primer (*Sma* I underlined) – SEQ ID NO:56 – according to human IL-2 sequence (NCBI accession number NM000586). The PCR product is cloned into the bluescript plasmid (NCBI accession number X52328) between *Pst* I and *Sma* I sites, to create a pBSSK-IL-2 plasmid.

To generate the chimeric soluble IL-15R $\alpha$ -IL-2 construct, the signal peptide and the extracellular domain of IL-15R $\alpha$  (nucleotides 1-697) were PCR amplified from pNoR15, using the sense primer -SEQ ID NO:57- 5'-GGGAAAGCTTAGTCCAGCGGTGTCCTGT-3' (primer 1, nested *Hind* III restriction site underlined) and the antisense primer -SEQ ID NO:58- 5'-AACTGCAGAGTGGTGTGCTGTGGCC-3' (primer 2, *Pst* I underlined).

The amplified product was then cloned between the *Hind III* and *Pst I* sites of pBSSK-IL-2.

In the final hybrid gene, the *Pst I* site (coding for the dipeptide Leu-Gln) behaved as a linker between the IL-15R $\alpha$  (5' end) and IL-2 (3' end) sequences. The sequence was controlled and the chimeric construct was digested from the bluescript plasmid between the *Hind III*/*Not I* sites and subcloned into the mammalian expression vector pKCR6 (31) at the *Eco RI* site. Dhfr- CHO cells were transfected with pKCR6-sIL-15R $\alpha$ -IL-2 using SuperFect Reagent (Qiagen, Courtaboeuf, France). Clones producing the fusion protein were detected using an ELISA for detection of human IL-2 (BioSource, Nivelles, Belgium). Three rounds of cloning were performed using increasing concentrations of methotrexate (Sigma). One clone selected at 5  $\mu$ M methotrexate produced about 4.3 mg/l of sIL-15R $\alpha$ -IL-2. The supernatants were concentrated by precipitation with ammonium sulfate at 60% saturation, loaded onto an IL-2 immunoaffinity column (mAb IL2.66), and the IL-2 fusion protein was purified as described (32). Its concentration was determined in the ELISA for human IL-2. Its purity was at least 80% with a molecular mass of 60 kDa, as assessed by SDS-PAGE after iodination with a chloramine T method as described previously (12). Full functionality of the IL-2 portion of the fusion protein was demonstrated in a CTLL-2 proliferation assay (cell proliferation kit II, Roche Diagnostics, Mannheim, Germany), using rIL-2 as standard. High affinity IL-15 binding of the IL-15R $\alpha$  portion was demonstrated using the surface plasmon resonance technology (Biacore AB, Uppsala, Sweden).

### *Production of IL-15 mutants*

25

The pEF-*neo* PPL SP-IL-15 (human) expression construct was built in the pEF-1/myc-His vector (In Vitrogen, ref V921-20). The rat preprolactin signal peptide (PPL SP) sequence was amplified by RT-PCR of mRNA prepared from GH4C1 cells (ATCC accession number CCL-82.2) using 5' GGGGTACCATCACCATGAACAGCCAAG 3' as sense primer (*Kpn I* site underlined) – SEQ ID NO:59 – and 5' CGGGATCCGGTCTGCACATTTTGGCAG 3' as anti-sense primer (*Bam HI* site underlined) – SEQ ID NO:60 –, according to *rattus norvegicus* preprolactin sequence (NCBI accession number AF022935). The mature human IL-15 coding sequence was

amplified by RT-PCR of mRNA from normal human keratinocytes prepared from foreskin obtained after circumcision, using 5' CGGGATCCAACTGGGTGAATGTAATAAG 3' as sense primer (*Bam* *H1* site underlined) – SEQ ID NO:61 – and 5' GGAATTCTCAAGAAGTGTTGATGAAC 3' as anti-sense primer (*Eco* *R1* site underlined) – SEQ ID NO:62 –, according to human IL-15 sequence (NCBI accession number NM000585). The PPL SP was introduced between the *Kpn* *I* and *Bam* *H1* sites of pEF-1/myc-His, and IL-15 between the *Bam* *H1* and *Eco* *R1* sites of pEF-1/myc-His.

The FLAG tag (DYKDDDDK ; SEQ ID NO:63) was introduced at the *Bam*H1 site between the PPL SP and the mature IL-15 protein coding sequence as a double stranded oligonucleotide (SEQ ID NO:64 = 5'- GATCGGACTACAAGGATGACGATGACAAGC -3' and SEQ ID NO:65 = 5'- GATCGCTTGTCATCGTCATCCTTGTAGTCC -3'). A bluescript plasmid containing the PPL-FLAG-IL-15 sequence was generated by subcloning the *Kpn* *I*/*Eco* *R1* fragment. Amino-acid switching was performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with the bluescript construct. Sequences were confirmed over the PPL-FLAG-IL-15 hybrid cDNA and the mutated *Kpn* *I*/*Eco* *R1* fragment was cloned back into pEF-1/myc-His. For the production of a FLAG-IL-15 mutant,  $3.2 \times 10^6$  adherent 293 c18 cells were transfected with 16  $\mu$ g of the mutated IL-15 expression construct in a 60 mm plate following a standard calcium phosphate protocol. After 6 h, the medium was replaced with fresh complete DMEM (Life Technologies, Cergy Pontoise, France) and supernatants were harvested 48 h after transfection.

### *Pepscan analysis*

The overlapping synthetic peptides were synthesized and screened using credit-card format mini-PEPSCAN cards (455 peptide format/card) as described previously (33). The 455-well credit-card format polyethylene cards, containing the covalently linked peptides, were incubated at 4°C overnight with the samples (soluble IL-15R $\alpha$ -IL-2 fusion protein) diluted in blocking solution containing 5% horse-serum (v/v) and 5% ovalbumin (w/v). After washing, the cards were incubated (1 h, 25°C) with the anti-human IL-2 antibody AF-202-NA (1  $\mu$ g/ml), washed and further incubated with peroxidase-coupled rabbit anti-goat IgGs at 1.3  $\mu$ g/ml (P 0160, DakoCytomation). After washing, the

peroxidase substrate 2,2'-azino-di-3-ethylbenzthiazoline sulfonate (ABTS) plus 2  $\mu$ l/ml 3%  $H_2O_2$  were added, and the color development was quantified at 1 h, using a CCD-camera and an image processing system. The setup consists of a CCD-camera and a 55 mm lens (Sony CCD Video Camara XC-77RR, Nikon micro-nikkor 55 mm f/2.8 lens), a camera adaptor (Sony Camara adaptor DC-77RR) and the Image Processing Software package Optimas, version 6.5 (Media Cybernetics, Silver Spring, MD), run on a Pentium II computer system. The CCD-camera is equipped with an orange filter that translates the green color of the ABTS substrate into grey values (arbitrary scale).

### *IL-15 binding assays*

Human rIL-15 was radio-labeled with [ $^{125}$ I]-iodine (specific radioactivity of around 2000 cpm/fmol) using a chloramine T method (34), and binding experiments were performed as described previously (12). Non specific binding was determined in the presence of 100 fold excess of unlabeled cytokine. For the IL-15 binding experiments, TF-1 cells were incubated with increasing concentrations of labeled rIL-15. Regression analysis of the binding data was accomplished using a one-site equilibrium binding equation (Grafit, Erithacus Software, Staines, UK) and data was plotted in the Scatchard coordinate system. For inhibition of IL-15 binding experiments, TF-1 cells were incubated with a fixed concentration of iodinated rIL-15 and increasing concentrations of FLAG-IL-15 or mutants or mAbs. Regression analysis of data was accomplished using a 4 parameter logistic equation (Grafit, Erithacus Software).

### *Proliferation assays*

The proliferative inducing activity of FLAG-IL-15 and mutants and the inhibitory activity of mAbs were assessed by [ $^3$ H]-thymidine incorporation on TF-1 $\beta$  cells. Cells were maintained in the culture medium for 3 days, washed twice, and starved for 2 h in the same medium without cytokine. They were plated at  $10^4$  cells in 100  $\mu$ l and cultured for 48 h in the medium supplemented with increasing concentrations of rIL-15, FLAG-IL-15 or mutant, or in the medium supplemented with a fixed concentration of rIL-15 and increasing concentration of mAbs. Cells were pulsed for 16 h with 0.5  $\mu$ Ci/well of [ $^3$ H]-

thymidine, harvested onto glass fiber filters, and cell-associated radioactivity was measured.

## 5 **Results**

### *Analysis of IL-15R $\alpha$ binding to IL-15 by a pepscan approach*

A pepscan approach was used in an attempt to identify IL-15 regions directly involved in  
 10 IL-15R $\alpha$  binding. For that purpose, a soluble fusion protein (sIL-15R $\alpha$ -IL-2) consisting of  
 the extracellular domain of human IL-15R $\alpha$  fused to human IL-2 was assayed for binding  
 to the 12-mer IL-15 peptides, using a polyclonal anti-human IL-2 antibody (AF-202-NA)  
 as the revealing antibody (Fig. 3A). Two main peaks of reactivity were observed that  
 corresponded to the binding of sIL-15R $\alpha$ -IL-2 with two different regions of the IL-15  
 15 sequence. Control experiments with a similar concentration (330 nM) of rIL-2 gave  
 background reactivity (Fig. 3A). Pepscan studies on 30-mer peptide of human IL-15  
 confirmed the reactivity of sIL-15R $\alpha$ -IL-2 with these two IL-15 regions. Analysis of the 2  
 sets of peptides (12-mer and 30-mer) associated with the reactivity allowed to assign the  
 following sequences as responsible for sIL-15R $\alpha$ -IL-2 binding:  $_{44}$ LLELQVISL $_{52}$  (peptide  
 20 1 ; SEQ ID NO:4) and  $_{64}$ ENLII $_{68}$  (peptide 2 ; SEQ ID NO:6). The first sequence is  
 located within helix B, and the second sequence in helix C (Fig. 3B).

### *IL-15 site-directed mutagenesis*

25 In order to confirm the involvement of the two peptidic regions identified by pepscan in  
 the binding to the IL-15R $\alpha$  chain, point mutations of IL-15 in these regions were carried  
 out. In order to introduce a substantial disturbance in the presumed receptor binding site,  
 non-polar hydrophobic side chains (L, V, I) and non-charged polar side chains (S, N, Q)  
 were replaced by charged groups (D, E or K), and charged polar side chains (E) were  
 30 replaced by oppositely charged groups (K). Mutants were generated at positions 44 to 52  
 (peptide 1) and positions 64 to 68 (peptide 2). Wild-type human IL-15 and mutants were  
 expressed as fusion proteins with a N-terminal FLAG peptide in the 293 c18 cells.

FLAG-IL-15 and mutants were then assayed for their ability to bind IL-15R $\alpha$  expressed by TF-1 cells (Figures 4A, 4B, 4C). For that purpose, a competition assay was used that allowed to compare the efficiencies of the different mutants to inhibit the binding of a low, non-saturating concentration of radio-iodinated rIL-15 to TF-1 cells. The competition curves are shown in Fig. 4A, 4B, 4C and the concentrations of mutants giving half maximal inhibitory effects (IC<sub>50</sub>s) are listed in Table I.

Table I

FLAG-IL-15 Proteins	IC <sub>50</sub> (pM)	Relative activity (% WT)
W T	26.1	100
L44D	ND	NA
L45D	10.1	258 $\pm$ 30
L45E	12.5	209 $\pm$ 10
E46K	13314.7	0.20 $\pm$ 0.01
L47D	ND	NA
Q48K	20.5	127 $\pm$ 27
V49D	347.7	8 $\pm$ 2
I50D	2949.8	0.88 $\pm$ 0.45
S51D	11.6	225 $\pm$ 36
L52D	10.9	239 $\pm$ 5
E64K	18.2	143 $\pm$ 43
N65K	26.6	98 $\pm$ 26
L66D	190.9	14 $\pm$ 8
L66E	407.1	6 $\pm$ 2
I67D	104.8	25 $\pm$ 6
I67E	63.7	41 $\pm$ 9
I68D	20.2	129 $\pm$ 28

TABLE I *Binding properties of the IL-15 mutants on the TF-1 cell line.* ND: not determined. NA: not applicable. Mean and standard deviations of the relative activities are from three independent experiments.

5 FLAG-IL-15 inhibited labeled rIL-15 binding with an IC<sub>50</sub> of 26 pM.

Mutations at three positions (E46, V49 and I50) within peptide 1 had profound effects on the affinity of IL-15, whereas mutation Q48K was without effect. Mutations at position L45 (L45D and L45E), S51 and L52 reproducibly resulted in an increased (2 to 3 fold) affinity of IL-15 in this competition assay. The mutants L44D and L47D could not be evaluated in this assay because of too low production levels in 293 c18 supernatants. Some mutations in the peptide 2 region (those directed to residues L66 and I67) also strongly reduced the affinity of IL-15, whereas mutations at positions E64, N65 and I68 were without significant effects.

15

Wild-type FLAG-IL-15 and mutants were then tested for their growth-promoting effects on the IL-15 responsive TF-1 $\beta$  cells (Figures 5A, 5B, 5C and table II).

Table II

FLAG-IL-15 proteins	Maximal induction (% WT)	EC <sub>50</sub> (pM)	Relative activity (% WT)
W T	100	6.0	100
L44D	0	> 20.0	< 30
L45D	100	1.7	353 ± 73
L45E	100	2.4	250 ± 21
E46K	> 20	> 1300.0	< 0.5
L47D	0	> 60.0	< 10
Q48K	100	4.8	125 ± 22
V49D	100	6.2	97 ± 55
I50D	> 10	> 60.0	< 10
S51D	100	1.9	316 ± 26
L52D	100	1.7	353 ± 91
E64K	20	≈ 0.8	NA
N65K	0	> 200.0	< 0.4
L66D	0	> 200.0	< 0.4
L66E	0	> 200.0	< 0.4
I67D	> 40	> 30.0	< 3
I67E	> 75	> 10.0	< 8
I68D	20	≈ 0.8	NA

5 TABLE II *Proliferative activities of the IL-15 mutants on TF-1β cells.* NA: not applicable. Mean and standard deviations of the relative activities are from three independent experiments.

10 The peptide 1 mutants displayed biological activities that correlated well with their IL-15Rα binding efficiencies measured on TF-1 cells: the L44D, E46K, L47D, and I50D



mutations resulted in a strong reduction of the biological activity of IL-15, whereas mutation Q48K was without significant effect, and mutations at positions L45, S51 and L52 induced a 2 to 4 fold increase in bioactivity. The only exception was mutant V49D which, despite a strongly reduced binding capacity, displayed nearly wild-type bioactivity.

5 In contrast, the correlation between biological activity on TF-1 $\beta$  cells and binding affinity on TF-1 cells was far weaker with mutants in the peptide 2 region. Mutant N65K who displayed a nearly wild-type binding affinity on TF-1 cells was inactive on TF-1 $\beta$  cells. Mutant E64K and I68D who also displayed nearly wild-type binding affinities behaved as partial agonists on TF-1 $\beta$  with maximal responses being about 20% that of wild-type IL-  
10 15. The only correlation was found for mutations at the L66 and I67 positions. The mutants L66D, L66E, I67D and I67E displayed reduced bioactivity with a ranked order of potencies similar to that seen in the competition binding assay.

### Discussion

15

As opposed to the IL-2R $\alpha$  chain which binds IL-2 with low affinity (35), the IL-15R $\alpha$  chain has been shown *per se* to display high affinity binding for IL-15 (11). The interface between IL-15 and IL-15R $\alpha$  therefore likely contributes to most of the free energy of binding of IL-15 to its functional high affinity ( $\alpha\beta\gamma$ ) receptor. To design proteins with  
20 agonist or antagonist properties of the IL-15 system, a good knowledge of the molecular features of the IL-15/IL-15R $\alpha$  interface is therefore desirable. No data are available so far on that topic and the main aim of this study was to contribute to the definition of the epitope in IL-15 responsible for the binding of IL-15R $\alpha$ .

Two regions were first identified by pepscan that specifically bind a soluble form of IL-  
25 15R $\alpha$ . The first one (<sub>44</sub>LLELQVISL<sub>52</sub>, peptide 1) is located in the B helix, while the second (<sub>64</sub>ENLII<sub>68</sub>, peptide 2) belongs to the C helix.

Mutagenesis studies confirmed the involvement of these two regions and enabled us to identify amino-acids that participate in receptor binding and induction of bio-activity.

Mutation at that position (I50D) strongly reduced the ability of IL-15 to bind to IL-15R $\alpha$   
30 as well as to induce cell proliferation, a result that might reflect a local conformational change that affect binding and signaling. However, this conformational change seems to not disturb the overall structure of the molecule.

E46, V49, L45, S51 and L52 were found to be involved in IL-15R $\alpha$  binding.

E46 was crucial, since replacement of its acidic side chain by a basic one (E46K) resulted in a complete loss of IL-15 binding to IL-15R $\alpha$  and bio-activity.

Replacement of the hydrophobic side chain of V49 by a negatively charged side chain (V49D) also resulted in a strong (13 fold) reduction of the affinity of IL-15 for IL-15R $\alpha$ .

5 Unexpectedly, the V49D mutant showed almost wild-type biological activity. A similar discrepancy between binding affinity and bio-activity has been reported for an IL-2 mutant (T51P) (36). This mutant was as active as wild-type IL-2, although it displayed a 10 fold lower receptor binding affinity. It has been shown that this mutant was deficient in inducing internalization of high-affinity receptors, thus resulting in longer duration of  
10 receptor occupancy and induction of biological response. Whether the V49D IL-15 analog exhibits similar properties needs to be checked.

Mutations at positions L45, S51 and L52 did not result in reduction but to an increase in binding and bio-activity, indicating that these residues are also involved in IL-15R $\alpha$  binding. The mutants L44D and L47D showed impaired biological responses, although  
15 their binding affinity could not be evaluated. Unexpectedly, mutant Q48K showed almost wild-type properties, although Q48 is positioned in the center of an epitope formed by amino-acids (L45, E46, V49, S51 and L52) which participate in receptor binding. Additional mutations of that residue might be required to reassess its potential involvement in receptor binding.

20

The results of mutagenesis in the peptide 2 region showed that among the 5 amino-acids evaluated (E64 to I68), only L66 and I67 seem to be involved in receptor binding. The mutants (L66D, L66E, I67D and I67E) displayed reduced binding affinities and corresponding reductions of their biological activities. Mutants E64K and I68D had  
25 affinities similar to that of wild-type IL-15, suggesting that E64 and I68 are not involved in IL-15R $\alpha$  binding. However, the mutants behaved as partial agonists in the proliferation assay. Since partial agonism is indicative of defective activation of the receptor (37), E64 and I68 might be involved in the recruitment of the IL-2R $\beta$ / $\gamma$  transduction complex. This conclusion might hold for N65 whose mutation (N65K) resulted in a loss of bio-activity  
30 without detectable alteration of the IL-15R $\alpha$  binding affinity. Mutagenesis of mouse IL-2 and molecular modeling studies (27,38) have indicated that, in addition to residue D20 located on helix A (24), the C helix of human IL-2 is also potentially involved in its interaction with IL-2R $\beta$ , and recent work has shown that a mutation in that helix (N88R)

resulted in a drastic (1000 fold) loss of IL-2 binding to IL-2R $\beta$  (26). Our results suggest that the corresponding region in human IL-15, especially residues E64, N65 and I68, participate also in the recruitment of the IL-2R $\beta$  chain.

The IL-15 mutants E64K, N65K and I68D display properties (low or no biological activity despite high affinity binding to IL-15R $\alpha$ ) that designate them as potential IL-15 antagonists. Preliminary experiments indeed indicate that N65K can inhibit IL-15 induced cell proliferation.

The region of IL-15 which corresponds to peptide 2 seems to participate both in IL-15R $\alpha$  and IL-2R $\beta$  binding. Mutagenesis revealed that all amino-acids of peptide 2 (E64 to I68) are involved in this process.

The involvement of the epitope corresponding to peptide 2 in both IL-15R $\alpha$  binding and IL-2R $\beta$  recruitment might have implications on the dynamics of the receptor assembly. IL-15 would first bind with high affinity to IL-15R $\alpha$  by engaging the peptide 1 and peptide 2 (or part of it) epitopes. Subsequent IL-2R $\beta$  recruitment could then involve the engagement of another part of the peptide 2 epitope. Alternatively, a conformational change could occur in which IL-2R $\beta$  would replace IL-15R $\alpha$  in binding to the peptide 2 epitope.

In the case of mouse IL-2, a sequence of helix B analogous to the epitope in IL-15 corresponding to peptide 1 has been shown to interact with IL-2R $\alpha$  (namely residues E76, P79, V83 and L86) (27). In the case of human IL-2, no mutations in the B helix that affect IL-2 binding to IL-2R $\alpha$  have been described so far, although molecular modeling has predicted a contact between helix B of human IL-2 (namely residues K64 and E68, or E61 and E62) and IL-2R $\alpha$  (38). In contrast, the region in IL-2 within helix C analogous to the epitope in IL-15 corresponding to peptide 2 does not appear to be involved in IL-2R $\alpha$  binding (27). Our results therefore indicate that the mode of interaction of IL-15 with IL-15R $\alpha$  is not completely homologous to the mode of interaction of IL-2 with IL-2R $\alpha$ . This may reflect the fact that IL-15 displays an affinity for its  $\alpha$  chain that is about 500 fold higher than the affinity of IL-2 for its  $\alpha$  chain.

In conclusion, we identified two regions in IL-15 that are involved in the binding to IL-15R $\alpha$ , one of them being also used to recruit the IL-2R $\beta$  transducing subunit. IL-15

muteins (L45D, L45E, S51D and L52D) which display binding and biological properties higher than those of wild-type IL-15 and therefore behave as super-agonists are valuable tools to expand lymphocyte subsets (*e.g.* NK cells, NK-T cells, CD8<sup>+</sup> memory T cells) and might be useful as therapeutic agents in patients with cancer or immunodeficiencies.

- 5 Other muteins (E64K, N65K and I68D) display properties that designate them as potential IL-15 antagonists, and might be useful in inflammatory diseases like rheumatoid arthritis and generalized Shwartzman reaction where IL-15 is thought to play an important role (22).

## 10 Footnotes

- The abbreviations used are: IL, interleukin; rIL, recombinant IL; IL-15R $\alpha$ , IL-15 receptor  $\alpha$  chain; NK, Natural Killer; Jak, Janus kinase; Stat, signal transducer and activator of transcription; Lck, lymphocyte specific tyrosine kinase; syk, Spleen tyrosine kinase; MAP, mitogen activated protein kinase; Bcl, B cell leukemia; GM-CSF, Granulocyte-
- 15 Macrophage colony stimulating factor; mAb, monoclonal antibody; ELISA, enzyme-linked immunosorbent assay; RIA, radio-immuno assay; PCR, polymerase chain reaction; Dhfr, dihydrofolate reductase; IC50, inhibitory concentration 50%; EC50, effective concentration 50%; SP, signal peptide; PPL, preprolactine.

## References

1. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., Johnson, L., Alderson, M. R., Watson, J. D., Anderson, D. M., and Giri, J. G. (1994) *Science* **264**, 965-968
2. Burton, J. D., Bamford, R. N., Peters, C., Grant, A. J., Kurys, G., Goldman, C. K., Brennan, J., Roessler, E., and Waldmann, T. A. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 4935-4939
3. Sprang, S. R., and Bazan, J. F. (1993) *Cur. Op. Struct. Biol.* **3**, 815-827
4. Carson, W. E., Giri, J. G., Lindeman, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M. A. (1994) *J. Exp. Med.* **180**, 1395-1403
5. Armitage, R. J., Macduff, B. M., J., E., Paxton, R., and Grabstein, K. H. (1995) *J. Immunol.* **154**, 483-490
6. Wilkinson, P. C., and Liew, F. Y. (1995) *J. Exp. Med.* **181**, 1255-1259
7. Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K. H., Kumaki, A., Namen, A., Park, L. S., Cosman, D., and Anerson, D. M. (1994) *EMBO J.* **13**, 2822-2830
8. Anderson, D. M., Kumaki, S., Ahdieh, M., Bertles, J., Tometsko, M., Loomis, A., Giri, J., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Valentine, V., Shapiro, D. N., Morris, S. W., Park, L. S., and Cosman, D. (1995) *J. Biol. Chem.* **270**, 29862-29869
9. Norman, D. G., Barlow, P. N., Baron, M., Day, A. J., Sim, R. B., and Campbell, I. D. (1991) *J. Mol. Biol.* **219**, 717-725
10. Minami, Y., Kono, T., Miyasaki, T., and Taniguchi, T. (1993) *Annu. Rev. Immunol.* **11**, 245-267
11. Giri, J. G., Anderson, D. M., Kumaki, S., Park, L. S., Grabstein, K. H., and Cosman, D. (1995) *J. Leukoc. Biol.* **57**, 763-766
12. Lehours, P., Raher, S., Dubois, S., Guo, J., Godard, A., and Jacques, Y. (2000) *Eur. Cytokine Netw.* **11**, 207-215
13. Johnston, J. A., Bacon, C. M., Finbloom, D. S., Rees, R. C., Kaplan, D., Shibuya, K., Ortaldo, J. R., Gupta, S., Chen, Y. Q., Giri, J. D., and O'Shea, J. J. (1995) *Proc. Natl. Acad. Sci. U. S. A.* **92**, 8705-8709

14. Miyasaki, T., Liu, Z.-J., Kawahara, A., Minami, Y., Yamada, K., Tsujimoto, Y., Barsoumian, E. L., Perlmutter, R. M., and Taniguchi, T. (1995) *Cell* **81**, 223-231
15. Bulanova, E., Budagian, V., Pohl, T., Krause, H., Durkop, H., Paus, R., and Bulfone-Paus, S. (2001) *J. Immunol.* **167**, 6292-6302
16. Pereno, R., Giron-Michel, J., Gaggero, A., Cazes, E., Meazza, R., Monetti, M., Monaco, E., Mishal, Z., Jasmin, C., Indiveri, F., Ferrini, S., and Azzarone, B. (2000) *Oncogene* **19**, 5153-5162
17. Bulfone-Paus, S. S., Bulanova, E., Pohl, T., Budagian, V., Durkop, H., Ruckert, R., Kunzendorf, U., Paus, R., and Krause, H. (1999) *Faseb J.* **13**, 1575-1585
18. Stevens, A. C., Matthews, J., Andres, P., Baffis, V., Zheng, X. X., Chae, D. W., Smith, J., Strom, T. B., and Maslinski, W. (1997) *Am. J. Physiol.* **272**, G1201-1208
19. Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., Brasel, K., Morrissey, P. J., Stocking, K., Schuh, J. C., Joyce, S., and Peschon, J. J. (2000) *J. Exp. Med.* **191**, 771-780
20. Lodolce, J. P., Burkett, P. R., Boone, D. L., Chien, M., and Ma, A. (2001) *J. Exp. Med.* **194**, 1187-1194
21. Li, X. C., Demirci, G., Ferrari-Lacraz, S., Groves, C., Coyle, A., Malek, T. R., and Strom, T. B. (2001) *Nat. Med.* **7**, 114-118
22. Fehniger, T. A., and Caligiuri, M. A. (2001) *Blood* **97**, 14-32
23. Fehniger, T. A., Cooper, M. A., and Caligiuri, M. A. (2002) *Cytokine Growth Factor Rev.* **13**, 169-183
24. Collins, L., Tsien, W. H., Seals, C., Hakimi, J., Weber, D., Bailon, P., Hoskings, J., Greene, W. C., Toome, V., and Ju, G. (1988) *Proc. Natl. Acad. Sci. U. S. A.* **85**, 7709-7713
25. Sauve, K., Nachman, M., Spence, C., Bailon, P., Campbell, E., Tsien, W. H., Kondas, J. A., Hakimi, J., and Ju, G. (1991) *Proc. Natl. Acad. Sci. U. S. A.* **88**, 4636-4640
26. Shanafelt, A. B., Lin, Y., Shanafelt, M. C., Forte, C. P., Dubois-Stringfellow, N., Carter, C., Gibbons, J. A., Cheng, S. L., Delaria, K. A., Fleischer, R., Greve, J. M., Gundel, R., Harris, K., Kelly, R., Koh, B., Li, Y., Lantz, L., Mak, P., Neyer, L.,

- Plym, M. J., Roczniak, S., Serban, D., Thrift, J., Tsuchiyama, L., Wetzel, M., Wong, M., and Zolotarev, A. (2000) *Nat. Biotechnol.* **18**, 1197-1202
27. Zurawski, S. M., Vega, F. J., Doyle, E. L., Huyghe, B., Flaherty, K., McKay, D. B., and Zurawski, G. (1993) *EMBO J.* **12**, 5113-5119
  28. Pettit, D. K., Bonnert, T. P., Eisenman, J., Srinivasan, S., Paxton, R., Beers, C., Lynch, D., Miller, B., Yost, J., Grabstein, K. H., and Gombotz, W. R. (1997) *J. Biol. Chem.* **272**, 2312-2318
  29. Farner, N. L., Gan, J., de Jong, J. L., Leary, T. P., Fenske, T. S., Buckley, P., Dunlap, S., and Sondel, P. M. (1997) *Cytokine* **9**, 316-327
  30. Weiss, A., Wiskocil, R.L., and Stobo, J.D. (1984) *J. Immunol.* **133**, 123-128.
  31. Matrisian, L. N., Bowden, G. T., Krieg, P., Fürstenberger, G., Briand, J. P., Leroy, P., and Breathnach, R. (1986) *Proc. Natl. Acad. Sci. U.S.A.* **83**, 9413-9417
  32. Blanc, C., Vusio, P., Schleinkofer, K., Boisteau, O., Pflanz, S., Minvielle, S., Grotzinger, J., Muller-Newen, G., Heinrich, P. C., Jacques, Y., and Montero-Julian, F. A. (2000) *J. Immunol. Methods* **241**, 43-59
  33. Slootstra, J. W., Puijk, W. C., Ligtoet, G. J., Langeveld, J. P., and Meloen, R. H. (1996) *Mol. Divers.* **1**, 87-96
  34. Tejedor, F., and Ballesta, J. P. G. (1982) *Anal. Biochem.* **127**, 143-149
  35. Greene, W. C., Robb, R. J., Svetlick, P. B., Rusk, C. M., Depper, J. M., and Leonard, W. J. (1985) *J. Exp. Med.* **162**, 363-368
  36. Chang, D. Z., Wu, Z., and Ciardelli, T. L. (1996) *J. Biol. Chem.* **271**, 13349-13355
  37. Black, J. (1989) *Science* **139**, 1550-1556
  38. Bamborough, P., Hedgecock, C. J., and Richards, W. G. (1994) *Structure* **2**, 839-851

### CLAIMS

1. Peptide which is part of the epitope in human IL-15 that is responsible for high-affinity binding of IL-15 to the IL-15Ralpha chain, characterized in that it has the sequence of the region of human mature wild-type IL-15 from L44 to L52 (SEQ ID NO:4), or the sequence of the region of human mature wild-type IL-15 from E64 to I68 (SEQ ID NO:6).
2. Nucleic acid coding for a peptide of claim 1.
3. IL-15 mutein, characterized in that it has a sequence that is derivable from human mature wild-type IL-15 by at least one substitution, deletion or addition within the region spanning from residue 44 to residue 52, and/or from residue 64 to residue 68, this residue numbering corresponding to the human mature wild-type IL-15, provided that the IL-15 mutein resulting therefrom has an affinity for binding to IL-15Ralpha that is either not significantly different from, or higher than the affinity of human mature wild-type IL-15 for binding to IL-15Ralpha.
4. IL-15 mutein according to claim 3, characterized in that said substitution is a replacement of at least one hydrophobic side chain selected from L, V and I, and/or of at least one non-charged polar side chain selected from S, N, and Q by a charged group selected from D, E, K, and R.
5. IL-15 mutein according to claim 3 or 4, characterized in that said substitution is a replacement of at least one charged polar side chain selected from E by the oppositely charged group K.
6. IL-15 mutein according to any one of claims 3-5, characterized in that it is an IL-15 agonist.
7. IL-15 mutein according to claim 6, characterized in that it has a sequence that is derivable from human mature wild-type IL-15 by substitution of at least one of residues 45, 51, 52.



8. IL-15 mutein according to claim 7, characterized in that it has a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 45 by D or E.
9. IL-15 mutein according to claim 8, characterized in that it has the sequence of SEQ ID NO:29 or SEQ ID NO:30.
10. IL-15 mutein according to claim 7, characterized in that it has a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 51 by D.
11. IL-15 mutein according to claim 10, characterized in that it has the sequence of SEQ ID NO:33.
12. IL-15 mutein according to claim 7, characterized in that it has a sequence has a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 52 by D.
13. IL-15 mutein according to claim 12, characterized in that it has the sequence of SEQ ID NO:37.
14. IL-15 mutein according to any one of claims 3-5, characterized in that it is an IL-15 antagonist candidate.
15. IL-15 mutein according to claim 14, characterized in that it has a sequence that is derivable from human mature wild-type IL-15 by substitution of at least one of residues 64, 65, 68.
16. IL-15 mutein according to claim 15, characterized in that it has a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 64 by K.
17. IL-15 mutein according to claim 16, characterized in that it has the sequence of SEQ ID NO:41.

18. IL-15 mutein according to claim 15, characterized in that it has a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 65 by K.
19. IL-15 mutein according to claim 18, characterized in that it has the sequence of SEQ ID NO:45.
20. IL-15 mutein according to claim 15, characterized in that it has a sequence that is derivable from human mature wild-type IL-15 by replacement of residue 68 by D.
21. IL-15 mutein according to claim 20, characterized in that it has the sequence of SEQ ID NO:47.
22. Nucleic acid coding for the IL-15 mutein of any one of claims 3-21, optionally contained within a vector.
23. Conservative fragment of the IL-15 mutein of any one of claims 3-21, which still comprises the mutated 44-52 region and/or mutated 64-68 region, provided that the IL-15 mutein fragment resulting therefrom still has an affinity for binding to IL-15Ralpha that is either not significantly different from, or higher than the affinity of human mature wild-type IL-15 for binding to IL-15Ralpha.
24. IL-15 mutein fragment according to claim 23, characterized in that it is an IL-15 agonist.
25. IL-15 mutein fragment according to claim 24, characterized in that it comprises the sequence of any one of SEQ ID NO:7-18.
26. IL-15 mutein fragment according to claim 25, characterized in that it is an IL-15 antagonist candidate.
27. IL-15 mutein fragment according to claim 26, characterized in that it comprises the sequence of any one of SEQ ID NO:19-28.

28. Nucleic acid coding for the IL-15 mutein fragment of any one of claims 23-27, optionally contained within a vector.
29. Drug which comprises an IL-15 mutein according to any one of claims 6-13, and/or an IL-15 mutein fragment according to claim 24 or 25, and which optionally comprises a pharmaceutically acceptable vehicle and/or carrier and/or diluent and/or adjuvant.
30. Use of an IL-15 mutein according to any one of claims 6-13, or of an IL-15 mutein fragment according to claim 24 or 25, for the manufacture of an anti-cancer or anti-immunodeficiency drug.
31. Process for screening for an IL-15 agonist or antagonist, characterized in that it comprises:
- i. providing a plurality of IL-15 muteins according to any one of claims 3-21, and/or of IL-15 mutein fragments according to any one of claims 23-27,
  - ii. comparing their respective binding affinity for IL15-Ralpha to the binding affinity of mature wild-type IL-15,
  - iii. selecting those muteins or mutein fragments which have a binding affinity that is not significantly different from, or that is higher than the one of mature wild-type IL-15.
32. Process according to claim 31, which is for screening for an IL-15 agonist, characterized in that it further comprises:
- iv. selecting at least one detectable IL15-inducible activity,
  - v. comparing the level of said activity that is induced in response to the muteins or fragments selected in step iii., to the one induced by mature wild-type IL-15,
  - vi. selecting those muteins or fragments which induce an activity level that is not significantly different from, or that is higher than the one of mature wild-type IL-15.
33. Process according to claim 31, which is for screening for an IL-15 antagonist, characterized in that it further comprises:
- iv. selecting at least one detectable IL15-inducible activity,

v. comparing the level of said activity that is induced in response to the muteins or fragments selected in step iii., to the one induced by mature wild-type IL-15,

vi. selecting those muteins or fragments which induce an activity level that is lower than the one of mature wild-type IL-15, or which induce no detectable level of activity.



### **ABSTRACT**

The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor  $\alpha$ -chain. Two IL-15 regions are involved in the formation of this epitope: the first region ( $_{44}$ LLELQVISL $_{52}$ , peptide 1) corresponds to a sequence located in the B helix and the second ( $_{64}$ ENLII $_{68}$ , peptide 2) to a sequence located in helix C.

Mutins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.



```

1  gactccgggt ggcaggcgc cgggggaatc ccagctgact cgctcactgc cttcgaagtc
61  cggcgccccc cgggaggga cgggtggcc ctgggtggcc gcacctccc ggctgcggtg gctgtcgccc
121  ccacccctgc agccaggact ttccatcatg catacaagat cgtattgtat tctaggaggc atcgtgggatg
181  tggagcaatg ttccatcatg ttccatgctg ttccatgctg cgtattgtat tctaggaggc atcgtgggatg
241  atgttagcag atagccagcc gaaacccct tgccatagcc agctcttctt caatactaa ggatttaccg
301  gatggctgct gaaacccct taatgagaaat ttcgaaacca catttgagaa gtatttccat ccagtgctac
361  tggctttgag ttctaaacag tcattttcta actgaagctg gcattcatgt cttcattttg
421  ttgtgtttac ttctaaacag tcattttcta actgaagctg gcattcatgt cttcattttg
481  ggctgtttca gtgcagggt tcctaaacca gaagccaact ggtgaatgt aataagtgtat
541  ttgaaaaaaa ttgaagatct tattcaatct atgcataatg atgctacttt atatacggaa
601  agtgatgttc acccagttg caaagtaaca gcaatgaagt gctttctctt ggagttacaa
661  gttatttcac ttgagtcgg agatgcaagt attcatgata cagtagaaaa tctgatcatc
721  ctagcaaaaa acagtttgtc ttctaattgg aatgtaacag aatctggatg caaagaatgt
781  gaggaactgg aggaaaaaaa tattaaagaa tttttgcaga gttttgtaca tattgtccaa
841  atgttcatca acacttcttg attgcaattg attcttttta aagtgtttct gttattaaaca
901  aacatcactc tgctgcttag acataacaaa acactcggca ttcaaatgt gctgtcaaaa
961  caagtttttc tgtcaagaag atgatacagc ctgggacag atgaaactctt agaaatgaag
1021  gcagaaaaat gtcattgagt aatatagtga ctatgaactt ctctcagact tactttactc
1081  atttttttaa tttattattg aaattgtaca tatttgtgga ataattgaaa atgttgaata
1141  aaaatatgta caagtgttgt tttttaagtt gcactgatata ttacctctt attgcaaaat
1201  agcatttgtt taagggtgat agtcaaatga ttatttgtg gggctgggta ccaatgctgc
1261  aggtcaacag ctatgcttgt aggtccttgc cagtgtggaa ccactgacta ctggctctca
1321  ttgacttctt tactaagcat agcaaacaga ggaagaattt gttatcagta agaaaaagaa
1381  gaactatatg tgaatcctct tctttatact gtaatttagt tattgatgta taaagcaact
1441  gttatgaaat aaagaaattg caataactgg caaaaaaaaa aaaaaaa

```

**SEQ ID NO : 1** Human IL-15 wild-type mature IL-15 (CDS from 373 to 861)

## **FIGURE 1A**



1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
31	VHPSCKVTAM	<sup>44</sup> KCFLLELQVI	<sup>52</sup> SLESGDASIH
61	<sup>64</sup> DTVENLI <sup>68</sup> ILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**SEQ ID NO :2**

**Human wild-type mature IL-15**

**FIGURE 1A (end)**

	646	672	
	ctc ttg gag tta caa gtt att tca ctt		<u>SEQ ID NO:3</u>
peptide 1:	45	51 52	
	L L E L Q V I S L		<u>SEQ ID NO:4</u>

	706	720	
	gaa aat ctg atc atc		<u>SEQ ID NO:5</u>
peptide 2:	64 65	68	
	E N L I I		<u>SEQ ID NO:6</u>

**FIGURE 1B**

45 51 52  
peptide 1 : L L E L Q V I S L SEQ ID NO :4

-----mutant peptides-----

L D E L Q V I S L	<u>SEQ ID NO :7</u>
L E E L Q V I S L	<u>SEQ ID NO :8</u>
L K E L Q V I S L	<u>SEQ ID NO :9</u>
L R E L Q V I S L	<u>SEQ ID NO :10</u>
L L E L Q V I D L	<u>SEQ ID NO :11</u>
L L E L Q V I E L	<u>SEQ ID NO :12</u>
L L E L Q V I K L	<u>SEQ ID NO :13</u>
L L E L Q V I R L	<u>SEQ ID NO :14</u>
L L E L Q V I S D	<u>SEQ ID NO :15</u>
L L E L Q V I S E	<u>SEQ ID NO :16</u>
L L E L Q V I S K	<u>SEQ ID NO :17</u>
L L E L Q V I S R	<u>SEQ ID NO :18</u>

Figure 2A

peptide 2 :	64 65 68 E N L I I	<u>SEQ ID NO :6</u>
-----mutant peptides-----		
	K N L I I	<u>SEQ ID NO :19</u>
	R N L I I	<u>SEQ ID NO :20</u>
	E D L I I	<u>SEQ ID NO :21</u>
	E E L I I	<u>SEQ ID NO :22</u>
	E K L I I	<u>SEQ ID NO :23</u>
	E R L I I	<u>SEQ ID NO :24</u>
	E N L I D	<u>SEQ ID NO :25</u>
	E N L I E	<u>SEQ ID NO :26</u>
	E N L I K	<u>SEQ ID NO :27</u>
	E N L I R	<u>SEQ ID NO :28</u>

**Figure 2B**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLELQVI	SLESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**L45D SEQ ID NO :29**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLEELQVI	SLESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**L45E SEQ ID NO :30**

**FIGURE 2C**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFL <b>K</b> ELQVI	SLESGDASIH
	64	68	
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**L45K SEQ ID NO :31**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFL <b>R</b> ELQVI	SLESGDASIH
	64	68	
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**L45R SEQ ID NO :32**

**FIGURE 2C (continued)**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	<b>D</b> LESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**S51D SEQ ID NO :33**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	<b>E</b> LESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**S51E SEQ ID NO :34**

**FIGURE 2C (continued)**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLELEQVI	<b>K</b> LESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**S51K SEQ ID NO :35**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLELEQVI	<b>R</b> LESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**S51R SEQ ID NO :36**

**FIGURE 2C (continued)**



1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SDESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**L52D SEQ ID NO :37**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SEESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**L52E SEQ ID NO :38**

**FIGURE 2C (continued)**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SKESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**L52K SEQ ID NO :39**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SRESGDASIH
	64 68		
61	DTVENLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**L52R SEQ ID NO :40**

**FIGURE 2C (end)**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SLESGDASIH
	64 68		
61	DTV <b>K</b> NLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**E64K SEQ ID NO :41**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SLESGDASIH
	64 68		
61	DTV <b>R</b> NLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**E64R SEQ ID NO :42**

**FIGURE 2D**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SLESGDASIH
	64 68		
61	DTVEDLIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**N65D SEQ ID NO :43**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SLESGDASIH
	64 68		
61	DTVEELIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**N65E SEQ ID NO :44**

**FIGURE 2D (continued)**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFELLEQVI	SLESGDASIH
	64 68		
61	DTVE <b>K</b> LIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**N65K SEQ ID NO :45**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFELLEQVI	SLESGDASIH
	64 68		
61	DTVE <b>R</b> LIILA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**N65R SEQ ID NO :46**

**FIGURE 2D (continued)**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SLESGDASIH
	64 68		
61	DTVENLIDLA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**I68D SEQ ID NO :47**

1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SLESGDASIH
	64 68		
61	DTVENLIELA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**I68E SEQ ID NO :48****FIGURE 2D (continued)**


1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SLESGDASIH
	64	68	
61	DTVENLI <b>K</b> LA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS

**I68K SEQ ID NO :49**




1	NWVNVISDLK	KIEDLIQSMH	IDATLYTESD
		44	52
31	VHPSCKVTAM	KCFLLELQVI	SLESGDASIH
	64	68	
61	DTVENLI <b>R</b> LA	NNSLSSNGNV	TESGCKECEE
91	LEEKNIKEFL	QSFVHIVQMF	INTS




**I68R SEQ ID NO :50**

**FIGURE 2D (end)**

**FIGURES 3A and 3B**



**FIGURE 4A****FIGURE 4B****FIGURE 4C**

**FIGURE 5A****FIGURE 5B****FIGURE 5C**

